ArticleFrontiers in reproductive health2026
Breastmilk transfer and infant exposure to atazanavir/ritonavir in breastfeeding women with HIV: results from IMPAACT 2026.
Article in Frontiers in reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Background: Breastfeeding offers significant health benefits, and guidance for women with HIV increasingly emphasizes individualized, informed infant-feeding decisions. Breastmilk antiretroviral transfer and safety data are needed to inform shared decision-making discussions across all settings. Methods: Breastmilk transfer of ritonavir (RTV)-boosted atazanavir (ATV) was evaluated in the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2026 study. Fourteen breastfeeding women with HIV receiving RTV boosted ATV 100/300 mg daily, as part of a multi-drug regimen, and their infants were enrolled in Kenya, Uganda, and South Africa between 5 and 9 days postpartum and followed through age 16-24 weeks. Paired maternal plasma, breastmilk, and infant plasma samples were collected at each visit. Concentrations were measured using validated LC-MS/MS methods. Relative infant dose (RID) was estimated assuming an infant milk intake of 150 mL/kg/day. Safety outcomes were prospectively assessed. Results: All 14 women reported exclusive breastfeeding. Median maternal plasma and breastmilk concentrations were 1,410 ng/mL and 432 ng/mL for ATV, and 217 ng/mL and 13.6 ng/mL for RTV, respectively. Median breastmilk-to-plasma ratios were 0.253 (ATV) and 0.081 (RTV). RID values were 1.27% (maximum 6.43%) for ATV and 0.12% (maximum 1.10%) for RTV. Infant plasma concentrations were below the lower limit of quantitation (ATV 23.4 ng/mL; RTV 9.8 ng/mL) in all 42 samples. No maternal adverse events occurred; three infants experienced unrelated grade 2 events. Conclusions: In this cohort, ATV and RTV were detectable in maternal plasma and breastmilk but not in infant plasma, with low RID estimates and a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.